此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Biomarker Feedback to Motivate Cessation in Pregnancy (MAW Phase 3)

2017年12月15日 更新者:Christi Patten、Mayo Clinic

Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women (MAW) - Phase 3 Pilot Clinical Trial

Phase 3 Pilot Clinical Trial.

研究概览

详细说明

Developing effective tobacco cessation interventions during pregnancy for American Indian and Alaska Native people is a national priority and will contribute to the U.S. public health objective of reducing tobacco-related cancer health disparities. The proposed project builds on the investigators' successful partnership with the Alaska Native community and previous work with Alaska Native pregnant women. The investigators propose to develop and test a novel biomarker feedback intervention relating cotinine levels in the urine of pregnant women with the woman and infant's likely exposure to the tobacco specific nitrosamine and carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK). This 5-year project will be conducted in three phases. In Phase 1 the investigators will utilize a non-randomized, clinical observational trial to examine biomarkers of nicotine and carcinogen exposure (urine cotinine and total NNAL [a metabolite of NNK], respectively) among 150 maternal-infant pairs with assessments conducted during pregnancy and at delivery. In Phase 2, the investigators will obtain qualitative feedback on the findings from Phase 1 through individual interviews conducted with 32 women who use tobacco to develop the biomarker feedback intervention messages. Phase 3 will consist of a formative evaluation of the biomarker feedback intervention with 60 pregnant women using a two-group randomized design to assess the intervention's feasibility and acceptability, and the biochemically confirmed abstinence rate at the end of pregnancy. All phases of the project will be guided by a Community Advisory Committee. Each phase is an important step to advance the investigators' understanding of the potential for biomarker feedback as a strategy to help Alaska Native pregnant women quit tobacco use. The potential reach of the intervention is significant from a public health perspective as over 600 tobacco users deliver each year at the Alaska Native Medical Center in Anchorage where the proposed project will take place. Developing effective interventions for tobacco cessation during pregnancy is important to reduce adverse health consequences for the mother and neonate and future risk of tobacco-caused cancers.

This is the third and final phase of the project.

研究类型

介入性

注册 (实际的)

60

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alaska
      • Anchorage、Alaska、美国、99577
        • Alaska Native Tribal Health Consortium

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Alaska Native
  • 18 years or older
  • provide written informed consent
  • be currently pregnant and at <24 weeks gestation
  • reside in Anchorage and plan to deliver at the ANMC
  • current tobacco user defined as any use of Iqmik, commercial ST, and/or cigarettes during the past 7 days.

Exclusion Criteria:

  • use of using nicotine replacement therapy or medications for tobacco cessation or participation in a behavioral cessation program within the past 30 days
  • another woman from the same household has enrolled.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Control condition
Control behavioral phone-based smoking cessation intervention
phone-based behavioral smoking cessation counseling
实验性的:Biomarker Feedback Intervention
Biomarker feedback plus behavioral phone-based smoking cessation intervention
Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
smoking abstinence in late pregnancy (self-reported abstinence verified with cotinine)
大体时间:at week 36 gestation or greater up to the time of delivery
self-reported abstinence verified with cotinine
at week 36 gestation or greater up to the time of delivery

次要结果测量

结果测量
措施说明
大体时间
Self-efficacy (Self-reported confidence scale)
大体时间:at week 36 gestation or greater up to the time of delivery
Self-reported confidence scale
at week 36 gestation or greater up to the time of delivery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Christi A Patten, PhD、Mayo Clinic

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2015年3月1日

初级完成 (实际的)

2017年12月1日

研究完成 (实际的)

2017年12月1日

研究注册日期

首次提交

2015年4月14日

首先提交符合 QC 标准的

2015年4月30日

首次发布 (估计)

2015年5月1日

研究记录更新

最后更新发布 (实际的)

2017年12月19日

上次提交的符合 QC 标准的更新

2017年12月15日

最后验证

2017年12月1日

更多信息

与本研究相关的术语

其他研究编号

  • 11-001144-02

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅